Blink® Tears eye drops + Investigational lipid eye drops
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Visual Acuity
Conditions
Visual Acuity
Trial Timeline
Sep 16, 2020 → Oct 10, 2020
NCT ID
NCT06131476About Blink® Tears eye drops + Investigational lipid eye drops
Blink® Tears eye drops + Investigational lipid eye drops is a phase 1 stage product being developed by Johnson & Johnson for Visual Acuity. The current trial status is completed. This product is registered under clinical trial identifier NCT06131476. Target conditions include Visual Acuity.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06131476 | Phase 1 | Completed |
Competing Products
13 competing products in Visual Acuity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 77 |
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 77 |
| Blink® Tears eye drops in a multidose bottle + Preservative-free investigational lubricating eye drops in a Novelia® eyedropper | Johnson & Johnson | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab + Aflibercept | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |
| Sham injections + Ranibizumab 0.5 mg | Novartis | Phase 3 | 77 |
| Ranibizumab + Dexamethasone implant and sham injections | Novartis | Phase 3 | 77 |
| Ranibizumab + Aflibercept | Novartis | Approved | 85 |
| Intravitreal Lucentis 0.5mg | Novartis | Pre-clinical | 23 |
| ZK200775 + ZK200775 + Sodium Chloride | Bayer | Phase 1 | 30 |
| Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) | Bayer | Pre-clinical | 20 |